The Puerto Rico Co. Redefining Pharmacy Benefit Management Across the U.S.

PharmPix is expanding its pharmacy benefit management services across the continental United States and its territories, bringing its proprietary OneArk clinical intelligence platform to new markets and customer segments.

The Guaynabo-based company, which serves more than 750,000 lives and was co-founded in 2009 by Dr. Martty Martínez Fraticelli and three fellow healthcare veterans, is preparing for entry into the Medicare market in early 2027 while strengthening its position in the commercial and government sectors across the country.

For its work in advancing a clinically driven model of pharmacy benefit management, Martínez Fraticelli recently received the 2026 PBMI Excellence Award for Clinical Innovation from the Pharmacy Benefit Management Institute, a national recognition that underscores PharmPix’s leadership in identifying risks at the point of sale rather than relying on retrospective analytics that arrive too late to protect patients.

What makes this recognition particularly significant is where the innovation originated. PharmPix was built from the ground up in Guaynabo, Puerto Rico, by Martínez Fraticelli, Jaime Figueroa, Iván López, and Herminio Correa.

What started as a local initiative has grown into a company now competing directly against industry giants like Express Scripts and CVS Caremark while remaining independent and clinician-led.

The company, which serves MCS, Rider, Bellavista, Auxilio Mutuo and numerous hospital systems, operates across the continental United States and its territories, with particular focus on the southeastern corridor where small and mid-sized health plans and employers represent strong opportunities.

OneArk’s prospective model challenges decades of industry practice where pharmacy benefit managers have primarily functioned as administrative claims processors rather than clinical partners with pharmacists.

For the Medicare market, the company will launch MedArk, a platform specifically designed to meet the complex needs of Medicare Part D plans.

“We believe a prescription can be processed correctly and still not be right for the person receiving it,” Martínez Fraticelli said in an interview with Caribbean Business. “Clinical innovation is not innovation for its own sake. It is using every tool we have and building the ones we do not have yet to notice what might otherwise be missed, protect a member from avoidable harm and protect a health plan from avoidable cost.”

A Model Built on Clinical Intelligence

Instead of waiting for problems to surface after a claim is paid, PharmPix’s proprietary OneArk platform identifies incorrect doses, dangerous interactions, duplicative therapies and age-related risks before a medication ever reaches a patient.

OneArk’s prospective model challenges decades of industry practice where pharmacy benefit managers have primarily functioned as administrative claims processors rather than clinical partners with pharmacists.

In an interview with Caribbean Business, Martínez Fraticelli explained that although most prescriptions arrive correctly, a significant portion do not. Between ten and fifteen percent of prescriptions contain inefficiencies that can lead to incorrect dosing, interactions with existing therapies, contraindications tied to age or renal function, and situations in which patients visit multiple physicians and pharmacies without any single provider having a complete view of their medication history.

PharmPix intervenes by alerting pharmacies and instructing them to contact prescribers before dispensing the medication. OneArk integrates adjudication, clinical logic, benefit configuration and real-time decision support into a single platform, allowing PharmPix to embed clinical programs directly into the adjudication process rather than relying on traditional retrospective analysis that comes after harm has already occurred.

The company tracks its impact through key performance indicators that measure interventions, success rates and cost avoidance.

Context: Regulatory Pressure, Industry Disruption

The timing of PharmPix’s national recognition arrives as the pharmacy benefit management industry faces significant headwinds.

The Consolidated Appropriations Act of 2026 will require PBMs to disclose far more information about pricing, rebates and spending, giving employers and health plans detailed visibility into pharmacy activity for the first time.

Martínez Fraticelli, however, believes transparency is only the beginning. He explained that transparency is the floor rather than the finish line, and that the real value lies in turning visibility into clinical action at the moment a prescription is filled.

“The patient who is better treated and has better outcomes is the least expensive patient,” he said. “Pharmacy should be seen as an investment in keeping patients healthier rather than a cost.”

This philosophy positions PharmPix differently from traditional PBMs, which have historically derived profits from rebates, spread pricing, and administrative fees. As regulators tighten transparency requirements and AI-native competitors emerge promising to dismantle legacy profit margins, PharmPix’s clinical-first approach offers an alternative model for an industry under siege.

Competing With Giants and Newcomers

PharmPix operates in the middle tier of the PBM landscape. Express Scripts generates more than $33 billion in annual pharmacy benefit revenue, while CVS Caremark exceeds $48 billion.

PharmPix, by contrast, operates at a fraction of the size of the Big Three. Yet it competes with a differentiated value proposition: independence, transparency and clinical leadership rather than massive scale.

The company also faces disruption from an unexpected direction. Direct-to-consumer pharmacy platforms such as Mark Cuban Cost Plus, Ro, Hims and TrumpRx are fragmenting the traditional PBM model by selling medications directly to consumers, often without any coordination with other providers treating the same patient.

This fragmentation creates gaps in care and duplicative therapies, exactly the kinds of problems PharmPix’s clinical model is designed to catch.

To address this emerging risk, the company is developing MemberApp, a mobile application scheduled for release in October that will allow patients to carry their pharmacy record on their phone and share it with physicians or PharmPix, consolidating medication history across multiple channels.

Specialty Drugs, Biosimilars, Medicare

PharmPix’s clinical strategy extends beyond safety into utilization management, specialty pharmacy, biosimilar conversion and formulary oversight.

The company has built a specialty hub that contracts with pharmacies based on therapeutic volume, which allows it to negotiate better discounts and improve access for patients. Biosimilars represent another area of focus, offering significant savings while maintaining clinical effectiveness for most patients.

Artificial intelligence plays a role in the company’s strategy, although PharmPix uses it cautiously. Martínez Fraticelli emphasized that AI should not override established clinical evidence. Instead, the company uses AI for predictive analytics across populations, identifying future risks based on medication patterns.

This approach contrasts with some competitors who are deploying AI more aggressively for autonomous prior authorization and real-time formulary optimization, but it aligns with PharmPix’s foundational belief that clinical judgment must remain central to every decision.

A Puerto Rico Innovation Goes National

The company demonstrates that sophisticated, technology-driven healthcare solutions can originate on the island and scale to national prominence. It is precisely the kind of biotech and healthcare-technology venture that fits Puerto Rico’s evolving industrial core, where manufacturing capability, technical talent, and clinical expertise combine to create exportable solutions.

Martínez Fraticelli envisions a future in which PBMs are highly technological, more effective and more efficient. He believes that clinical intelligence will drive better outcomes and reduce operational costs.

The PBMI Excellence Award affirms that vision. PharmPix’s prospective, clinically driven and technologically integrated model offers a blueprint for a PBM industry under pressure to deliver more value with greater transparency.

As the company scales its footprint across the United States and prepares to enter the Medicare market, Martínez Fraticelli’s core philosophy remains unchanged. Seeing the entire pharmacy picture is the only way to protect patients from avoidable harm and plans from avoidable cost.

For a local company that started with a conviction about what pharmacy benefit management should be, national expansion and an award-winning innovation validate not just a business model, but a Puerto Rico-born approach to industry transformation.